Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma

Robert T O'Donnell, Bryan R. Leigh, Scott D Christensen, Desireé S. Goldstein, David L. Kukis, Sui Shen, Aina Yuan, Diane A. DeNardo, Linda A. Kroger, Gerald L Denardo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Standard therapy for AIDS associated NHL (AANHL) is toxic and often ineffective. Radioimmunotherapy (RIT) is an appealing alternative to chemotherapy because of the radiosensitivity of NHL and the ability of the Lyre-1 monoclonal antibody to target therapeutic irradiation to NHL while relatively sparing normal tissue. A Phase I/II study of 90Y-2IT-BAD-Lym-1 was designed specifically for RIT of AANHL. The first patient has been treated with 15 mCi (7.5 mCi/m2) of 90Y-2IT-BAD-Lym-1, after an imaging dose of 111In-2IT-BAD-Lym-1. Before RIT, AANHL in the maxillary sinus extended into the oral cavity and axillary adenopathy was present. Imaging showed excellent accumulation of 111In-2IT-BAD-Lym-1 in the tumors. Substantial shrinkage of the oral lymphoma was observed 18 hours after the therapy dose of 90Y-2IT-BAD-Lym-1 and axillary adenopathy had disappeared by one week after RIT. Transient Grade IV myelosuppression was the only notable toxicity. Further PIT cycles were precluded by development of an antibody response (HAMA) against Lym-1. This novel preliminary study has shown that Lym-1 can target AANHL and produce significant tumor regression thereby providing encouragement to proceed with additional patients.

Original languageEnglish (US)
Pages (from-to)167-176
Number of pages10
JournalCancer Biotherapy and Radiopharmaceuticals
Volume14
Issue number3
StatePublished - 1999

Fingerprint

Radioimmunotherapy
Lymphoma
Acquired Immunodeficiency Syndrome
Maxillary Sinus
Poisons
Radiation Tolerance
Antibody Formation
Mouth
Neoplasms
Therapeutics
Monoclonal Antibodies
2IT-BAD-Lym-1 monoclonal antibody
Drug Therapy

Keywords

  • Acquired immunodeficiency syndrome
  • Lym-1
  • Non-Hodgkin's lymphoma
  • Radioimmunotherapy
  • Yttrium-90

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma. / O'Donnell, Robert T; Leigh, Bryan R.; Christensen, Scott D; Goldstein, Desireé S.; Kukis, David L.; Shen, Sui; Yuan, Aina; DeNardo, Diane A.; Kroger, Linda A.; Denardo, Gerald L.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 14, No. 3, 1999, p. 167-176.

Research output: Contribution to journalArticle

O'Donnell, RT, Leigh, BR, Christensen, SD, Goldstein, DS, Kukis, DL, Shen, S, Yuan, A, DeNardo, DA, Kroger, LA & Denardo, GL 1999, 'Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma', Cancer Biotherapy and Radiopharmaceuticals, vol. 14, no. 3, pp. 167-176.
O'Donnell, Robert T ; Leigh, Bryan R. ; Christensen, Scott D ; Goldstein, Desireé S. ; Kukis, David L. ; Shen, Sui ; Yuan, Aina ; DeNardo, Diane A. ; Kroger, Linda A. ; Denardo, Gerald L. / Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma. In: Cancer Biotherapy and Radiopharmaceuticals. 1999 ; Vol. 14, No. 3. pp. 167-176.
@article{de12ab5285614ca38c9683dec5371fc5,
title = "Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma",
abstract = "Standard therapy for AIDS associated NHL (AANHL) is toxic and often ineffective. Radioimmunotherapy (RIT) is an appealing alternative to chemotherapy because of the radiosensitivity of NHL and the ability of the Lyre-1 monoclonal antibody to target therapeutic irradiation to NHL while relatively sparing normal tissue. A Phase I/II study of 90Y-2IT-BAD-Lym-1 was designed specifically for RIT of AANHL. The first patient has been treated with 15 mCi (7.5 mCi/m2) of 90Y-2IT-BAD-Lym-1, after an imaging dose of 111In-2IT-BAD-Lym-1. Before RIT, AANHL in the maxillary sinus extended into the oral cavity and axillary adenopathy was present. Imaging showed excellent accumulation of 111In-2IT-BAD-Lym-1 in the tumors. Substantial shrinkage of the oral lymphoma was observed 18 hours after the therapy dose of 90Y-2IT-BAD-Lym-1 and axillary adenopathy had disappeared by one week after RIT. Transient Grade IV myelosuppression was the only notable toxicity. Further PIT cycles were precluded by development of an antibody response (HAMA) against Lym-1. This novel preliminary study has shown that Lym-1 can target AANHL and produce significant tumor regression thereby providing encouragement to proceed with additional patients.",
keywords = "Acquired immunodeficiency syndrome, Lym-1, Non-Hodgkin's lymphoma, Radioimmunotherapy, Yttrium-90",
author = "O'Donnell, {Robert T} and Leigh, {Bryan R.} and Christensen, {Scott D} and Goldstein, {Desire{\'e} S.} and Kukis, {David L.} and Sui Shen and Aina Yuan and DeNardo, {Diane A.} and Kroger, {Linda A.} and Denardo, {Gerald L}",
year = "1999",
language = "English (US)",
volume = "14",
pages = "167--176",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma

AU - O'Donnell, Robert T

AU - Leigh, Bryan R.

AU - Christensen, Scott D

AU - Goldstein, Desireé S.

AU - Kukis, David L.

AU - Shen, Sui

AU - Yuan, Aina

AU - DeNardo, Diane A.

AU - Kroger, Linda A.

AU - Denardo, Gerald L

PY - 1999

Y1 - 1999

N2 - Standard therapy for AIDS associated NHL (AANHL) is toxic and often ineffective. Radioimmunotherapy (RIT) is an appealing alternative to chemotherapy because of the radiosensitivity of NHL and the ability of the Lyre-1 monoclonal antibody to target therapeutic irradiation to NHL while relatively sparing normal tissue. A Phase I/II study of 90Y-2IT-BAD-Lym-1 was designed specifically for RIT of AANHL. The first patient has been treated with 15 mCi (7.5 mCi/m2) of 90Y-2IT-BAD-Lym-1, after an imaging dose of 111In-2IT-BAD-Lym-1. Before RIT, AANHL in the maxillary sinus extended into the oral cavity and axillary adenopathy was present. Imaging showed excellent accumulation of 111In-2IT-BAD-Lym-1 in the tumors. Substantial shrinkage of the oral lymphoma was observed 18 hours after the therapy dose of 90Y-2IT-BAD-Lym-1 and axillary adenopathy had disappeared by one week after RIT. Transient Grade IV myelosuppression was the only notable toxicity. Further PIT cycles were precluded by development of an antibody response (HAMA) against Lym-1. This novel preliminary study has shown that Lym-1 can target AANHL and produce significant tumor regression thereby providing encouragement to proceed with additional patients.

AB - Standard therapy for AIDS associated NHL (AANHL) is toxic and often ineffective. Radioimmunotherapy (RIT) is an appealing alternative to chemotherapy because of the radiosensitivity of NHL and the ability of the Lyre-1 monoclonal antibody to target therapeutic irradiation to NHL while relatively sparing normal tissue. A Phase I/II study of 90Y-2IT-BAD-Lym-1 was designed specifically for RIT of AANHL. The first patient has been treated with 15 mCi (7.5 mCi/m2) of 90Y-2IT-BAD-Lym-1, after an imaging dose of 111In-2IT-BAD-Lym-1. Before RIT, AANHL in the maxillary sinus extended into the oral cavity and axillary adenopathy was present. Imaging showed excellent accumulation of 111In-2IT-BAD-Lym-1 in the tumors. Substantial shrinkage of the oral lymphoma was observed 18 hours after the therapy dose of 90Y-2IT-BAD-Lym-1 and axillary adenopathy had disappeared by one week after RIT. Transient Grade IV myelosuppression was the only notable toxicity. Further PIT cycles were precluded by development of an antibody response (HAMA) against Lym-1. This novel preliminary study has shown that Lym-1 can target AANHL and produce significant tumor regression thereby providing encouragement to proceed with additional patients.

KW - Acquired immunodeficiency syndrome

KW - Lym-1

KW - Non-Hodgkin's lymphoma

KW - Radioimmunotherapy

KW - Yttrium-90

UR - http://www.scopus.com/inward/record.url?scp=0032998005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032998005&partnerID=8YFLogxK

M3 - Article

C2 - 10850301

AN - SCOPUS:0032998005

VL - 14

SP - 167

EP - 176

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 3

ER -